

1  
2  
3  
4  
5 **Intracellular pH Regulates Cancer and Stem Cell Behaviors:**  
6 **A Protein Dynamics Perspective**  
7  
8

9 Yi Liu, Katharine A. White<sup>1</sup> and Diane L. Barber<sup>2</sup>  
10

11 <sup>1</sup>Department of Cell and Tissue Biology, University of California San Francisco,  
12 San Francisco, CA 94143, USA  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 Keywords: intracellular pH; cancer; stem cell; protein structure; protonation  
23  
24  
25

26 <sup>1</sup>Current Address: Department of Chemistry and Biochemistry, Harper Cancer Research  
27 Institute, University of Notre Dame, South Bend, IN 46617, USA  
28

29 <sup>2</sup>Correspondence  
30 Diane L. Barber  
31 Department of Cell and Tissue Biology  
32 Box 0512  
33 513 Parnassus Ave.  
34 San Francisco, CA 94143  
35 USA  
36 [diane.barber@ucsf.edu](mailto:diane.barber@ucsf.edu)  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 **Abstract**

48 The International Society of Cancer Metabolism (ISCaM) meeting on Cancer Metabolic  
49 Rewiring, held in Braga Portugal in October 2019, provided an outstanding forum for  
50 investigators to present current findings and views, and discuss ideas and future directions on  
51 fundamental biology as well as clinical translations. The first session on *Cancer pH Dynamics*  
52 was preceded by the opening keynote presentation from our group entitled *Intracellular pH*  
53 *Regulation of Protein Dynamics: From Cancer to Stem Cell Behaviors*. In this review we  
54 introduce a brief background on intracellular pH (pHi) dynamics, including how it is regulated as  
55 well as functional consequences, summarize key findings included in our presentation, and  
56 conclude with perspectives on how understanding the role of pHi dynamics in stem cells can be  
57 relevant for understanding how pHi dynamics enables cancer progression.

58 **Introduction**

59 Intracellular pH (pHi) was previously thought to be mostly constant for cellular homeostasis and  
60 possibly dysregulated in diseases. We now know, however, that pHi is dynamic in normal cells  
61 and clearly dysregulated in a number of diseases. In normal cells, pHi changes during cell cycle  
62 progression, increasing ~ 0.3-0.4 pH units at the end of S phase and if this increase is blocked,  
63 G2/M is delayed with increased inhibitory phosphorylation of Cdk1-Tyr15 and suppressed cyclin  
64 B1 expression (1-3). Additionally, pHi dynamics regulates cell-substrate adhesion remodeling  
65 and migration, with increased pHi enabling both behaviors (4-7). Emerging evidence also  
66 indicates a critical role for increased pHi in epithelial plasticity, including epithelial to  
67 mesenchymal transition (EMT) (8) and stem cell differentiation (9-12). Moreover, it is now well  
68 established that dysregulated pHi is seen with many diseases, most notably cancers, which often  
69 have a constitutively increased pHi (13-18), and neurodegenerative disorders, which are  
70 associated with a constitutively decreased pHi (19, 20). Our review focuses on dysregulated pHi  
71 dynamics in cancer; however, another feature of cancers is a dysregulated extracellular pH that is  
72 lower (~ 7.0) compared with normal tissues (~ 7.4).

73 Although many factors contribute to pHi dynamics, the major regulators in most  
74 mammalian cells are plasma membrane ion exchangers, including the Na<sup>+</sup>-H<sup>+</sup> exchanger NHE1,  
75 the Na<sup>+</sup>-HCO<sub>3</sub><sup>-</sup> transporter NBC, and the Na<sup>+</sup>-dependent Cl<sup>-</sup>-HCO<sub>3</sub><sup>-</sup> transporter NDCBE, which  
76 are acid-extruders, and Cl<sup>-</sup>-HCO<sub>3</sub><sup>-</sup> exchangers of the anion exchanger (AE) family, which are  
77 acid loaders (21-23). The BioParadigms Solute Carrier tables<sup>33</sup> are an excellent resource on the  
78 classification, expression, and transport characteristics of these ion exchangers. Additional  
79 plasma membrane ion transport proteins that contribute to pHi dynamics, albeit to less of an  
80 extent, include V-ATPases and monocarboxylate transporters of the MCT family. The broad  
81 range of ion transport proteins regulate pHi dynamics through changes in their expression and  
82 activity, the latter mostly mediated by posttranslational modifications as many are substrates of  
83 key signaling kinases, including for NHE1, p90rsk (24), Akt (25, 26), the Rho kinase ROCK  
84 (27), and the Ste20 kinase MAP4K4 (28), previously termed NIK. Experimentally, these  
85 exchangers can be pharmacologically or genetically targeted to understand how they contribute  
86 to pHi dynamics and how pHi dynamics regulates cell behaviors.

87 We have a relatively strong understanding of how changes in pHi are generated and the  
88 effects of pHi changes on myriad cell functions. However, a mechanistic understanding of how  
89 pHi changes regulate cell behaviors remains understudied, particularly effects on signaling  
90 networks and protein functions. At the ISCaM meeting we presented our work on how changes

<sup>3</sup> <http://slc.bioparadigms.org/>

92 in pH<sub>i</sub> regulate protein dynamics to enable cancer and stem cell behaviors, which we summarize  
93 in this review. Key to pH-regulated protein structure and function is considering protonation and  
94 deprotonation as a protein posttranslational modification, analogous to posttranslational  
95 modification by phosphorylation, acetylation, and methylation as we previously described (29).  
96 However, studying protonation and deprotonation as a posttranslational modification is more  
97 difficult compared with other posttranslational modifications because it is not catalyzed by an  
98 enzyme and cannot be detected by mass spectrometry or antibodies. Furthermore, many  
99 endogenous “pH sensors” or proteins that are regulated by pH dynamics within the cellular range  
100 are coincidence (AND-gate) detectors with their structural conformations, activities, or binding  
101 affinities dependent on multiple posttranslational modifications, most commonly  
102 phosphorylation or dephosphorylation and protonation or deprotonation.  
103

#### 104 **Intracellular pH and cancer cell behaviors: From the protein view**

105 Most cancer cells have a higher pH<sub>i</sub> compared with untransformed cells, regardless of the  
106 mutational landscape or tissue origin. This higher pH<sub>i</sub> enables many cancer behaviors, including  
107 increased proliferation, directional migration, tumorigenesis, and most recently recognized, the  
108 oncogenic and tumor-suppressor functions of proteins with charge-changing mutations (Fig. 1).  
109 At the ISCaM meeting we presented our findings on pH sensors regulating cell migration and  
110 tumorigenesis as well as how pH<sub>i</sub> dynamics in cancer cells affect the functions of proteins with  
111 somatic mutations encoding arginine to histidine substitutions.

112 *Cell migration* is confirmed to be regulated by pH<sub>i</sub> in many cell types and species (6, 30-  
113 34). An increased pH<sub>i</sub> of ~ 0.3-0.4 units is seen in migrating cells and preventing the increased  
114 pH<sub>i</sub> inhibits migratory rate and directionality, and impairs cell polarity. Our presentation  
115 described several pH sensors we identified in atomistic detail that collectively regulate different  
116 aspects of migration. These include guanine nucleotide exchange factors for the low molecular  
117 weight GTPase Cdc42 involved in cell polarity (35), talin binding to actin filaments (36) and  
118 focal adhesion kinase (FAK) activity for cell-substrate adhesion dynamics (5) as well as cofilin  
119 for actin polymerization (37). The single histidine in cofilin, His133 (human), has an upshifted  
120 pKa to ~ 7.2 and must be neutral for increased cofilin activity (Fig. 1A). However, cofilin is a  
121 coincidence detector and full activity also requires dephosphorylation of Ser3 (Fig. 1A) by one  
122 of several phosphatases, which releases an autoinhibited interaction between phosphorylated  
123 serine and lysine 126 and 127 to allow binding to actin filaments. This AND-gate regulation  
124 enables signaling mechanisms to increase cofilin activity in time (with migratory cues) and space  
125 (at the leading edge of a migrating cell), and highlights that for many pH sensors a change in  
126 protonation state does not function as a binary switch.

127 *Tumorigenesis and dysplasia* are enabled by increased pH<sub>i</sub> regulated by NHE1, NBCs  
128 and MCTs, including tumor cell proliferation, growth, and survival (38-40). Our presentation  
129 included two of our recent key findings on pH<sub>i</sub> and tumorigenesis. First, that increased pH<sub>i</sub> from  
130 ~ 7.30 to ~ 7.65 in Drosophila eye epithelia by overexpressing Drosophila *dnhe2*, an ortholog of  
131 mammalian NHE1, is sufficient to induce dysplasia in the absence of an activated oncogene (41).  
132 Second, that β-catenin, an adherens junction and Wnt pathway protein is a pH sensor, with pH<sub>i</sub>  
133 not regulating its activity but rather its stability, which decreases at pH<sub>i</sub> > 7.5 (42). Using a  
134 phenotype screen, we found that overexpressing β-catenin suppresses dysplasia in Drosophila  
135 eye epithelia with constitutively increased pH<sub>i</sub> induced by overexpression of *dnhe2*. These data  
136 suggested a lower abundance of β-catenin at higher pH<sub>i</sub>, which we confirmed in mammalian  
137 cells. We also resolved the pH sensing mechanism of His36 (human) in the N-terminus of β-

138 catenin, which when neutral (at higher pH<sub>i</sub>) increases binding affinity for the E3 ligase β-TrCP1.  
139 However, like cofilin described above, β-catenin is a coincidence detector requiring both a  
140 neutral His36 and phosphorylated flanking Ser33 and Ser37 for binding β-TrCP1 (Fig. 1B). The  
141 role of phosphorylated serines in enabling proteasome-mediated degradation of β-catenin has  
142 long been recognized (43). The importance of a neutral His36 for binding β-TrCP1 is evident in  
143 the crystal structure of β-TrCP1 in complex with an N-terminal β-catenin peptide (44) (PDB:  
144 1P22), which shows the proximity of β-catenin-His36 and β-TrCP1-Lys365 (Fig. 1B). This  
145 suggests that binding would be electrostatically unfavorable with a protonated His36 at lower  
146 pH<sub>i</sub>. Importantly, the DSxxHS motif is conserved in all species of β-catenin and occurs in a  
147 number of other β-TrCP1 target proteins (45), including the transmembrane protein polycystin 2,  
148 the tumor suppressor tensin 2, the centrosomal protein Cep97, the hedgehog pathway protein  
149 Gli3, and myosin-XVIIIa, suggesting these substrates may have similar pH sensitive binding to  
150 β-TrCP1 and regulated protein stability. We also described that a cancer-associated somatic  
151 mutation, β-catenin-H36R, is insensitive to pH<sub>i</sub>-regulated degradation and, when expressed in  
152 Drosophila eye epithelia, enhances Wnt pathway activity, causes tissue overgrowth growth, and  
153 induces ectopic tumors. With this mutation, β-catenin stability could be retained at the higher  
154 pH<sub>i</sub> of a cancer cell and enable tumorigenesis. As described in the section below, this is an  
155 example of a charge-changing mutation that confers a loss of pH sensing.

156 *Charge-changing somatic mutations* can confer a change in pH sensing and enable cancer  
157 behaviors specifically at increased pH<sub>i</sub>. We recently showed that recurrent arginine to histidine  
158 mutations in p53 and EGFR can confer a gain in pH sensing to the mutant proteins. Arginine,  
159 with a pKa of 12, will be protonated regardless of pH<sub>i</sub> while histidine, with a pKa near neutral,  
160 can titrate with cellular changes in pH<sub>i</sub>. We found that a highly recurrent arginine to histidine  
161 mutation in the tumor suppressor p53 (p53-R273H) could confer pH-dependent DNA binding  
162 and transcription of p53 target genes, with decreased transcription at a higher pH<sub>i</sub> of 7.6  
163 compared with 7.2 (46). The crystal structure of wild-type p53 (47) (PDB: 4HJE) and mutant  
164 p53-R273H (48) (PDB: 4IBW) in complex with DNA suggests that wild-type Arg273 forms an  
165 electrostatic interaction with the negatively charged phosphate-backbone of DNA (Fig 1C). At  
166 the lower pH<sub>i</sub> of a non-transformed cell, His273 is likely protonated and retains some binding to  
167 the negatively-charged DNA but, at the higher pH<sub>i</sub> of a cancer cell, His273 is likely  
168 deprotonated, reducing DNA binding and expression of p53 target genes (Fig 1D). Importantly,  
169 lowering pH<sub>i</sub> in cancer cells expressing p53-R273H recovered p53 transcriptional activity and  
170 p53-dependent cell death in response to double-strand breaks (46). We also showed that a  
171 cancer-associated arginine to histidine substitution in the epidermal growth factor receptor  
172 (EGFR-R776H) that is recurrent in lung cancers confers pH sensing to the mutant protein.  
173 Increasing pH<sub>i</sub> from 7.2 to 7.6 increases activity of EGFR-R776H but not wild-type receptor,  
174 and increases cell proliferation and cellular transformation in cells expressing the mutant but not  
175 wild-type receptor (46). These results suggest that charge-changing mutations can confer a gain  
176 in pH-sensing not seen with the wild-type protein. This work also indicates that charge-changing  
177 somatic mutations can confer dynamic function to mutant proteins, specifically inactivating a  
178 tumor suppressor and specifically activating an oncogene at the increased pH<sub>i</sub> of cancer.  
179

## 180 **Intracellular pH and epithelial plasticity: Focus on stem cell differentiation**

181 Recent findings indicate that pH<sub>i</sub> dynamics is a key regulator of epithelial plasticity, with  
182 increased pH<sub>i</sub> enabling EMT (8) and epithelial branching morphogenesis (49) as well as  
183 differentiation of melanocytes (50), embryonic and adult stem cells (9, 11), and mesenchymal

184 (12) and cardiomyocyte (10) stem cells. These findings raise questions on the role of pH<sub>i</sub>  
185 dynamics in morphogenesis and animal development, which remain largely unresolved. New  
186 genetically-encoded tools to measure pH<sub>i</sub> (51) and genetic and pharmacological approaches to  
187 selectively change pH<sub>i</sub> temporally and spatially will enable new studies necessary to resolve  
188 pH<sub>i</sub>-regulated developmental processes with promise for new approaches to correct impaired  
189 morphogenesis.

190 Toward a goal of resolving the role of pH<sub>i</sub> dynamics in cell fate decisions, at the ISCaM  
191 meeting we discussed our findings on pH<sub>i</sub>-regulated embryonic and adult stem cell  
192 differentiation. As we previously described (11), with differentiation of naïve clonal mouse  
193 embryonic stem cells (mESC) to primed epiblast-like cells there is an NHE1-dependent transient  
194 increase in pH<sub>i</sub> of ~ 0.3 units (Fig. 2A). Preventing this increase in pH<sub>i</sub> blocks differentiation, as  
195 indicated by sustained expression of the mESC markers Rex1, Stra8, and Nanog, and attenuated  
196 expression of the epiblast markers Brachyury, fibroblast growth factor 5, and Pax6. An increase  
197 in pH<sub>i</sub> is also necessary for differentiation of adult follicle stem cells in the *Drosophila* ovary to  
198 prefollicle cells and follicle cells (9, 11) (Fig. 2B), the later necessary for germ cell maturation.  
199 Consistent with germ cells requiring enrichment from differentiated follicle cells, preventing the  
200 increase in pH<sub>i</sub> along the follicle stem cell lineage impairs ovary morphology and adult  
201 oogenesis and substantially decreases fertility (9). These findings were obtained by genetically  
202 silencing *Drosophila dnhe2*, an acid extruder, or overexpressing a newly identified *Drosophila*  
203 *ae2*, an ortholog of the mammalian acid loader AE2.

204 There are several important questions to resolve on the role of pH<sub>i</sub> dynamics in stem cell  
205 differentiation. First is whether pH<sub>i</sub> is a conserved regulator of stem cell differentiation in  
206 different tissues, perhaps using established and well characterized models for intestinal epithelial  
207 (52) and skin epidermal (53) stem cell lineages. Second is how pH<sub>i</sub> dynamics regulates activity  
208 of pathways and functions of proteins with established roles in stem cell behaviors. One  
209 possibility is a role for pH sensing by β-catenin (as described above) in Wnt signaling, because  
210 high Wnt pathway activity (54) at low pH<sub>i</sub> may retain self-renewal of stem cells and inhibit  
211 differentiation. Third is whether pH<sub>i</sub>-regulated stem cell differentiation can inform regenerative  
212 medicine approaches to correct or restore impaired cell and tissue functions.

#### 213 **Integrating pH<sub>i</sub> dynamics in cancer and stem cells**

214 To consider how pH<sub>i</sub> dynamics in stem cells and cancer might be linked, we concluded our  
215 presentation by showing new data on pH<sub>i</sub> heterogeneity in spheroids of clonal human lung  
216 cancer cells (Fig. 2C). Using H1299 cells expressing the previously described (41) genetically  
217 encoded and ratiometric pH biosensor mCherry-pHluorin, we observe distinct intercellular  
218 differences in pH<sub>i</sub> when grown in 3D (Fig. 2C). Distinct pH heterogeneity (including  
219 intracellular and extracellular pH) is seen in cancer spheroids (55-58) and a mouse model of  
220 breast ductal carcinoma (59); however, whether this heterogeneity reflects differences in  
221 mutational signatures, cell identity, phenotypes, or epithelial or metabolic plasticity remains  
222 unresolved. For example, might cells with a lower pH<sub>i</sub> be stem-like tumor initiating cells? Could  
223 cells with a higher pH<sub>i</sub> have increased glycolysis to fuel rapid proliferation or be undergoing  
224 EMT for metastasis? The possibility that a lower pH<sub>i</sub> could enable tumor initiating cells raises  
225 caution on the idea of lowering pH<sub>i</sub> to limit cancer progression. Tumor heterogeneity, whether  
226 genetic, epigenetic, or phenotypic, is increasingly being recognized as a challenge for cancer  
227 therapies (60, 61), and improved understanding of the determinants and consequences of pH<sub>i</sub>  
228 heterogeneity could contribute to resolving these therapeutic challenges.

230 The field has taken a first important step in identifying a number of normal and  
231 pathological cell behaviors regulated by pH<sub>i</sub> dynamics. A second step in understanding how pH<sub>i</sub>  
232 regulates the signaling pathways mediating these behaviors is now emerging. A third step of  
233 improved mechanistic understanding is an important future direction to resolve design principles  
234 and functions of pH sensitive proteins mediating pH<sub>i</sub>-regulated cell behaviors. This third step is  
235 experimentally challenging and remains largely unexplored, but holds promise for identifying  
236 new therapeutic targets and informing the design of therapeutics for regenerative medicine and  
237 treating diseases with dysregulated pH<sub>i</sub> dynamics, including cancer.

238

239

#### 240 **Acknowledgements**

241 This work was supported by National Institutes of Health grants F32CA177055 (KAW) and  
242 R01CA197855 and R01GM11634 (DLB). We thank members of the Barber laboratory for their  
243 contributions and suggestions. We apologize for not being able to include all relevant  
244 publications on the topics we present because of space limitations.

245

#### 246 **Author Contributions**

247 All authors contributed to obtaining data included in the figures, including data on pH<sub>i</sub> and  
248 cancer (KAW, DLB) and pH<sub>i</sub> and stem cell differentiation (YL, DLB). All authors contributed to  
249 writing and editing the manuscript.

250

#### 251 **Conflict of Interest Statement**

252 The authors declare no direct or perceived conflict of interest.

253

254

255

#### 256 **References**

257

- 258 1. Flinck, M., Kramer, S.H., Schnipper, J., Andersen, A.P. and Pedersen, S.F. (2018). The  
259 acid-base transport proteins NHE1 and NBCn1 regulate cell cycle progression in human  
260 breast cancer cells. *Cell Cycle* 17, 1056-1067. doi: 10.1080/15384101.2018.1464850
- 261 2. Ochi, H., Aoto, S., Tachibana, K., Hara, M. and Chiba, K. (2016). Block of CDK1-  
262 dependent polyadenosine elongation of Cyclin B mRNA in metaphase-i-arrested starfish  
263 oocytes is released by intracellular pH elevation upon spawning. *Mol Reprod Dev* 83, 79-  
264 87. doi: 10.1002/mrd.22599
- 265 3. Putney, L.K. and Barber, D.L. (2003). Na-H exchange-dependent increase in intracellular  
266 pH times G2/M entry and transition. *J Biol Chem* 278, 44645-9. doi:  
267 10.1074/jbc.M308099200
- 268 4. Cardone, R.A., Casavola, V. and Reshkin, S.J. (2005). The role of disturbed pH dynamics  
269 and the Na<sup>+</sup>/H<sup>+</sup> exchanger in metastasis. *Nat Rev Cancer* 5, 786-95. doi:  
270 10.1038/nrc1713
- 271 5. Choi, C.H., Webb, B.A., Chimenti, M.S., Jacobson, M.P. and Barber, D.L. (2013). pH  
272 sensing by FAK-His58 regulates focal adhesion remodeling. *J Cell Biol* 202, 849-59. doi:  
273 10.1083/jcb.201302131
- 274 6. Denker, S.P. and Barber, D.L. (2002). Cell migration requires both ion translocation and  
275 cytoskeletal anchoring by the Na-H exchanger NHE1. *J Cell Biol* 159, 1087-96. doi:  
276 10.1083/jcb.200208050

277 7. Stock, C. and Schwab, A. (2015). Ion channels and transporters in metastasis. *Biochim  
278 Biophys Acta* 1848, 2638-46. doi: 10.1016/j.bbamem.2014.11.012

279 8. Amith, S.R., Wilkinson, J.M. and Fliegel, L. (2016). Na<sup>+</sup>/H<sup>+</sup> exchanger NHE1 regulation  
280 modulates metastatic potential and epithelial-mesenchymal transition of triple-negative  
281 breast cancer cells. *Oncotarget* 7, 21091-113. doi: 10.18632/oncotarget.8520

282 9. Benitez, M., Tatapudy, S., Liu, Y., Barber, D.L. and Nystul, T.G. (2019). Drosophila  
283 anion exchanger 2 is required for proper ovary development and oogenesis. *Dev Biol* 452,  
284 127-133. doi: 10.1016/j.ydbio.2019.04.018

285 10. Li, X., Karki, P., Lei, L., Wang, H. and Fliegel, L. (2009). Na<sup>+</sup>/H<sup>+</sup> exchanger isoform 1  
286 facilitates cardiomyocyte embryonic stem cell differentiation. *Am J Physiol Heart Circ  
287 Physiol* 296, H159-70. doi: 10.1152/ajpheart.00375.2008

288 11. Ulmschneider, B., Grillo-Hill, B.K., Benitez, M., Azimova, D.R., Barber, D.L. and  
289 Nystul, T.G. (2016). Increased intracellular pH is necessary for adult epithelial and  
290 embryonic stem cell differentiation. *J Cell Biol* 215, 345-355. doi:  
291 10.1083/jcb.201606042

292 12. Gao, W., Zhang, H., Chang, G., Xie, Z., Wang, H., Ma, L., et al. (2014). Decreased  
293 intracellular pH induced by cariporide differentially contributes to human umbilical cord-  
294 derived mesenchymal stem cells differentiation. *Cell Physiol Biochem* 33, 185-94. doi:  
295 10.1159/000356661

296 13. Cardone, R.A., Alfarouk, K.O., Elliott, R.L., Alqahtani, S.S., Ahmed, S.B.M., Aljarbou,  
297 A.N., et al. (2019). The Role of Sodium Hydrogen Exchanger 1 in Dysregulation of  
298 Proton Dynamics and Reprogramming of Cancer Metabolism as a Sequela. *Int J Mol Sci*  
299 20. doi: 10.3390/ijms20153694

300 14. Stock, C. and Pedersen, S.F. (2017). Roles of pH and the Na<sup>(+)</sup>/H<sup>(+)</sup> exchanger NHE1 in  
301 cancer: From cell biology and animal models to an emerging translational perspective?  
302 *Semin Cancer Biol* 43, 5-16. doi: 10.1016/j.semcan.2016.12.001

303 15. Swietach, P. (2019). What is pH regulation, and why do cancer cells need it? *Cancer  
304 Metastasis Rev* 38, 5-15. doi: 10.1007/s10555-018-09778-x

305 16. Webb, B.A., Chimenti, M., Jacobson, M.P. and Barber, D.L. (2011). Dysregulated pH: a  
306 perfect storm for cancer progression. *Nat Rev Cancer* 11, 671-7. doi: 10.1038/nrc3110

307 17. White, K.A., Grillo-Hill, B.K. and Barber, D.L. (2017a). Cancer cell behaviors mediated  
308 by dysregulated pH dynamics at a glance. *J Cell Sci* 130, 663-669. doi:  
309 10.1242/jcs.195297

310 18. Parks, S.K., Chiche, J. and Pouyssegur, J. (2013). Disrupting proton dynamics and energy  
311 metabolism for cancer therapy. *Nat Rev Cancer* 13, 611-23. doi: 10.1038/nrc3579

312 19. Harguindeguy, S., Reshkin, S.J., Orive, G., Arranz, J.L. and Anitua, E. (2007). Growth and  
313 trophic factors, pH and the Na<sup>+</sup>/H<sup>+</sup> exchanger in Alzheimer's disease, other  
314 neurodegenerative diseases and cancer: new therapeutic possibilities and potential  
315 dangers. *Curr Alzheimer Res* 4, 53-65. doi: 10.2174/156720507779939841

316 20. Majdi, A., Mahmoudi, J., Sadigh-Eteghad, S., Golzari, S.E., Sabermarouf, B. and  
317 Reyhani-Rad, S. (2016). Permissive role of cytosolic pH acidification in  
318 neurodegeneration: A closer look at its causes and consequences. *J Neurosci Res* 94, 879-  
319 87. doi: 10.1002/jnr.23757

320 21. Boedtkjer, E., Bunch, L. and Pedersen, S.F. (2012). Physiology, pharmacology and  
321 pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1: similarities,

322 differences, and implications for cancer therapy. *Curr Pharm Des* 18, 1345-71. doi:  
323 10.2174/138161212799504830

324 22. Casey, J.R., Grinstein, S. and Orlowski, J. (2010). Sensors and regulators of intracellular  
325 pH. *Nat Rev Mol Cell Biol* 11, 50-61. doi: 10.1038/nrm2820

326 23. Parker, M.D. and Boron, W.F. (2013). The divergence, actions, roles, and relatives of  
327 sodium-coupled bicarbonate transporters. *Physiol Rev* 93, 803-959. doi:  
328 10.1152/physrev.00023.2012

329 24. Takahashi, E., Abe, J., Gallis, B., Aebersold, R., Spring, D.J., Krebs, E.G., et al. (1999).  
330 p90(RSK) is a serum-stimulated Na<sup>+</sup>/H<sup>+</sup> exchanger isoform-1 kinase. Regulatory  
331 phosphorylation of serine 703 of Na<sup>+</sup>/H<sup>+</sup> exchanger isoform-1. *J Biol Chem* 274, 20206-  
332 14. doi: 10.1074/jbc.274.29.20206

333 25. Meima, M.E., Webb, B.A., Witkowska, H.E. and Barber, D.L. (2009). The sodium-  
334 hydrogen exchanger NHE1 is an Akt substrate necessary for actin filament reorganization  
335 by growth factors. *J Biol Chem* 284, 26666-75. doi: 10.1074/jbc.M109.019448

336 26. Snabaitis, A.K., Cuello, F. and Avkiran, M. (2008). Protein kinase B/Akt phosphorylates  
337 and inhibits the cardiac Na<sup>+</sup>/H<sup>+</sup> exchanger NHE1. *Circ Res* 103, 881-90. doi:  
338 10.1161/CIRCRESAHA.108.175877

339 27. Tominaga, T., Ishizaki, T., Narumiya, S. and Barber, D.L. (1998). p160ROCK mediates  
340 RhoA activation of Na-H exchange. *EMBO J* 17, 4712-22. doi:  
341 10.1093/emboj/17.16.4712

342 28. Yan, W., Nehrke, K., Choi, J. and Barber, D.L. (2001). The Nck-interacting kinase (NIK)  
343 phosphorylates the Na<sup>+</sup>-H<sup>+</sup> exchanger NHE1 and regulates NHE1 activation by platelet-  
344 derived growth factor. *J Biol Chem* 276, 31349-56. doi: 10.1074/jbc.M102679200

345 29. Schonichen, A., Webb, B.A., Jacobson, M.P. and Barber, D.L. (2013). Considering  
346 protonation as a posttranslational modification regulating protein structure and function.  
347 *Annu Rev Biophys* 42, 289-314. doi: 10.1146/annurev-biophys-050511-102349

348 30. Jensen, H.H., Pedersen, G.A., Morgen, J.J., Parsons, M., Pedersen, S.F. and Nejsum, L.N.  
349 (2019). The Na(+) /H(+) exchanger NHE1 localizes as clusters to cryptic lamellipodia  
350 and accelerates collective epithelial cell migration. *J Physiol* 597, 849-867. doi:  
351 10.1113/JP277383

352 31. Magalhaes, M.A., Larson, D.R., Mader, C.C., Bravo-Cordero, J.J., Gil-Henn, H., Oser,  
353 M., et al. (2011). Cortactin phosphorylation regulates cell invasion through a pH-  
354 dependent pathway. *J Cell Biol* 195, 903-20. doi: 10.1083/jcb.201103045

355 32. Parks, S.K. and Pouyssegur, J. (2015). The Na(+)/HCO3(-) Co-Transporter SLC4A4  
356 Plays a Role in Growth and Migration of Colon and Breast Cancer Cells. *J Cell Physiol*  
357 230, 1954-63. doi: 10.1002/jcp.24930

358 33. Patel, H. and Barber, D.L. (2005). A developmentally regulated Na-H exchanger in  
359 Dictyostelium discoideum is necessary for cell polarity during chemotaxis. *J Cell Biol*  
360 169, 321-9. doi: 10.1083/jcb.200412145

361 34. Schwab, A. and Stock, C. (2014). Ion channels and transporters in tumour cell migration  
362 and invasion. *Philos Trans R Soc Lond B Biol Sci* 369, 20130102. doi:  
363 10.1098/rstb.2013.0102

364 35. Frantz, C., Karydis, A., Nalbant, P., Hahn, K.M. and Barber, D.L. (2007). Positive  
365 feedback between Cdc42 activity and H<sup>+</sup> efflux by the Na-H exchanger NHE1 for  
366 polarity of migrating cells. *J Cell Biol* 179, 403-10. doi: 10.1083/jcb.200704169

367 36. Srivastava, J., Barreiro, G., Groscurth, S., Gingras, A.R., Goult, B.T., Critchley, D.R., et  
368 al. (2008). Structural model and functional significance of pH-dependent talin-actin  
369 binding for focal adhesion remodeling. *Proc Natl Acad Sci U S A* 105, 14436-41. doi:  
370 10.1073/pnas.0805163105

371 37. Frantz, C., Barreiro, G., Dominguez, L., Chen, X., Eddy, R., Condeelis, J., et al. (2008).  
372 Cofilin is a pH sensor for actin free barbed end formation: role of phosphoinositide  
373 binding. *J Cell Biol* 183, 865-79. doi: 10.1083/jcb.200804161

374 38. Andersen, A.P., Samsoe-Petersen, J., Oernbo, E.K., Boedtkjer, E., Moreira, J.M.A.,  
375 Kveiborg, M., et al. (2018). The net acid extruders NHE1, NBCn1 and MCT4 promote  
376 mammary tumor growth through distinct but overlapping mechanisms. *Int J Cancer* 142,  
377 2529-2542. doi: 10.1002/ijc.31276

378 39. Chiche, J., Le Fur, Y., Vilmen, C., Frassineti, F., Daniel, L., Halestrap, A.P., et al. (2012).  
379 In vivo pH in metabolic-defective Ras-transformed fibroblast tumors: key role of the  
380 monocarboxylate transporter, MCT4, for inducing an alkaline intracellular pH. *Int J  
381 Cancer* 130, 1511-20. doi: 10.1002/ijc.26125

382 40. Pouyssegur, J., Franchi, A. and Pages, G. (2001). pH<sub>i</sub>, aerobic glycolysis and vascular  
383 endothelial growth factor in tumour growth. *Novartis Found Symp* 240, 186-96;  
384 discussion 196-8. doi: 10.1002/0470868716.ch13

385 41. Grillo-Hill, B.K., Choi, C., Jimenez-Vidal, M. and Barber, D.L. (2015). Increased H(+)  
386 efflux is sufficient to induce dysplasia and necessary for viability with oncogene  
387 expression. *eLife* 4. doi: 10.7554/eLife.03270

388 42. White, K.A., Grillo-Hill, B.K., Esquivel, M., Peralta, J., Bui, V.N., Chire, I., et al. (2018).  
389 beta-Catenin is a pH sensor with decreased stability at higher intracellular pH. *J Cell Biol*  
390 217, 3965-3976. doi: 10.1083/jcb.201712041

391 43. Stamos, J.L. and Weis, W.I. (2013). The beta-catenin destruction complex. *Cold Spring  
392 Harb Perspect Biol* 5, a007898. doi: 10.1101/cshperspect.a007898

393 44. Wu, G., Xu, G., Schulman, B.A., Jeffrey, P.D., Harper, J.W. and Pavletich, N.P. (2003).  
394 Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and  
395 lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. *Mol Cell* 11, 1445-56. doi:  
396 45. Shafique, S., Younis, S., Niaz, H. and Rashid, S. (2016). Elucidation, functional  
397 clustering and structural characterization of betaTrCP1 substrates through a molecular  
398 dynamics study. *Mol Biosyst* 12, 2233-46. doi: 10.1039/c6mb00189k

399 46. White, K.A., Ruiz, D.G., Szpiech, Z.A., Strauli, N.B., Hernandez, R.D., Jacobson, M.P.,  
400 et al. (2017). Cancer-associated arginine-to-histidine mutations confer a gain in pH  
401 sensing to mutant proteins. *Sci Signal* 10. doi: 10.1126/scisignal.aam9931

402 47. Chen, G., Hou, Z., Gulbranson, D.R. and Thomson, J.A. (2010). Actin-myosin  
403 contractility is responsible for the reduced viability of dissociated human embryonic stem  
404 cells. *Cell Stem Cell* 7, 240-8. doi: 10.1016/j.stem.2010.06.017

405 48. Eldar, A., Rozenberg, H., Diskin-Posner, Y., Rohs, R. and Shakked, Z. (2013). Structural  
406 studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor  
407 mutations via alternative protein-DNA interactions. *Nucleic Acids Res* 41, 8748-59. doi:  
408 10.1093/nar/gkt630

409 49. Jenkins, E.C., Jr., Debnath, S., Gundry, S., Gundry, S., Uyar, U. and Fata, J.E. (2012).  
410 Intracellular pH regulation by Na(+)/H(+) exchanger-1 (NHE1) is required for growth  
411 factor-induced mammary branching morphogenesis. *Dev Biol* 365, 71-81. doi:  
412 10.1016/j.ydbio.2012.02.010

413 50. Natarajan, V., Raja, D.A., Gotherwal, V., Subramaniam, Y.J., Sultan, F., Vats, A., et al.  
 414 (2019). pH controlled histone acetylation amplifies melanocyte differentiation program  
 415 downstream of MITF. *bioRxiv*, 545392. doi: 10.1101/545392

416 51. Grillo-Hill, B.K., Webb, B.A. and Barber, D.L. (2014). Ratiometric imaging of pH  
 417 probes. *Methods Cell Biol* 123, 429-48. doi: 10.1016/B978-0-12-420138-5.00023-9

418 52. Gehart, H. and Clevers, H. (2019). Tales from the crypt: new insights into intestinal stem  
 419 cells. *Nat Rev Gastroenterol Hepatol* 16, 19-34. doi: 10.1038/s41575-018-0081-y

420 53. Gonzales, K.A.U. and Fuchs, E. (2017). Skin and Its Regenerative Powers: An Alliance  
 421 between Stem Cells and Their Niche. *Dev Cell* 43, 387-401. doi:  
 422 10.1016/j.devcel.2017.10.001

423 54. Kretzschmar, K. and Clevers, H. (2017). Wnt/beta-catenin signaling in adult mammalian  
 424 epithelial stem cells. *Dev Biol* 428, 273-282. doi: 10.1016/j.ydbio.2017.05.015

425 55. Alvarez-Perez, J., Ballesteros, P. and Cerdan, S. (2005). Microscopic images of  
 426 intraspheroidal pH by 1H magnetic resonance chemical shift imaging of pH sensitive  
 427 indicators. *MAGMA* 18, 293-301. doi: 10.1007/s10334-005-0013-z

428 56. Lee, A.H. and Tannock, I.F. (1998). Heterogeneity of intracellular pH and of mechanisms  
 429 that regulate intracellular pH in populations of cultured cells. *Cancer Res* 58, 1901-8. doi:  
 430 57. McIntyre, A., Hulikova, A., Ledaki, I., Snell, C., Singleton, D., Steers, G., et al. (2016).  
 431 Disrupting Hypoxia-Induced Bicarbonate Transport Acidifies Tumor Cells and  
 432 Suppresses Tumor Growth. *Cancer Res* 76, 3744-55. doi: 10.1158/0008-5472.CAN-15-  
 433 1862

434 58. Swietach, P., Wigfield, S., Cobden, P., Supuran, C.T., Harris, A.L. and Vaughan-Jones,  
 435 R.D. (2008). Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular  
 436 pH in three-dimensional multicellular growths. *J Biol Chem* 283, 20473-83. doi:  
 437 10.1074/jbc.M801330200

438 59. Lobo, R.C., Hubbard, N.E., Damonte, P., Mori, H., Penzvalto, Z., Pham, C., et al. (2016).  
 439 Glucose Uptake and Intracellular pH in a Mouse Model of Ductal Carcinoma In situ  
 440 (DCIS) Suggests Metabolic Heterogeneity. *Front Cell Dev Biol* 4, 93. doi:  
 441 10.3389/fcell.2016.00093

442 60. Hausser, J. and Alon, U. (2020). Tumour heterogeneity and the evolutionary trade-offs of  
 443 cancer. *Nat Rev Cancer* 20, 247-257. doi: 10.1038/s41568-020-0241-6

444 61. Quintanal-Villalonga, A., Chan, J.M., Yu, H.A., Pe'er, D., Sawyers, C.L., Sen, T., et al.  
 445 (2020). Lineage plasticity in cancer: a shared pathway of therapeutic resistance. *Nat Rev  
 446 Clin Oncol*. doi: 10.1038/s41571-020-0340-z

447

448

## 449 Figure Legends

450

451 **Figure 1.** The higher pH<sub>i</sub> of cancer cells enables many behaviors, including directional  
 452 migration and tumorigenesis as well as the tumorigenic functions of proteins with charge-  
 453 changing arginine to histidine mutations. **(A)** Cell migration is in part dependent on increased  
 454 activity of coflin with increased pH<sub>i</sub>. Cofilin is a coincidence-regulated pH sensor that is  
 455 activated by deprotonation of His133 (cyan) and dephosphorylation of Ser3 (magenta) for actin  
 456 polymerization enabling cell migration. **(B)** Dysplasia is associated with increased pH<sub>i</sub>, which  
 457 decreases  $\beta$ -catenin stability.  $\beta$ -catenin is a coincidence-regulated pH sensor with deprotonation  
 458 of His36 (cyan) and phosphorylation of Ser33/37 by GSK3 $\beta$  enabling binding to the E3 ligase  $\beta$ -

459 TrCP1 for targeting to the proteasome for degradation. Crystal structure data show that  $\beta$ -  
460 catenin-His36 is in close proximity to  $\beta$ -TrCP1-Lys365, which suggest that binding would be  
461 electrostatically unfavorable with a protonated His36 at lower pH<sub>i</sub>. **(C)** Charge changing somatic  
462 mutations can confer pH-regulated protein activity. Structure of wild-type p53 (top) and mutant  
463 p53-R273H (bottom) in complex DNA indicating an electrostatic interaction of Arg273 with the  
464 negatively charged phosphate-backbone of DNA that could be partially enabled by protonated,  
465 but not neutral, His273.

466

467 **Figure 2.** **(A)** Schematic showing that clonal self-renewing mESC (Naïve), derived from the  
468 inner cell mass of the early blastocyst, have a lower pH<sub>i</sub> than differentiated primed epiblast-like  
469 stem cells (EpiSC), which are analogous to cells in the late epiblast stage. **(B)** Schematic of  
470 Drosophila germarium showing an increase in pH<sub>i</sub> from self-renewing follicle stem cell (Follicle  
471 SC) to differentiated prefollicle and follicle cell. **(C)** Image of lung cancer H1299 cells  
472 expressing the pH<sub>i</sub> biosensor mCherry-pHluorin and grown in Matrigel as 3D spheroids shows  
473 intracellular pH<sub>i</sub> heterogeneity that might reflect phenotypic heterogeneity, such as cells with a  
474 higher pH<sub>i</sub> undergoing EMT and cells with a lower pH<sub>i</sub> being self-renewing tumor initiating  
475 stem-like cells.

476






Fig. 1. Liu et al.

**A**

Late Blastocyst



Early Blastocyst



EpiSC  
pHi 7.65



Naïve  
pHi 7.35

**B**


Follicle cell  
pHi 7.45

Prefollicle  
pHi 7.2

Follicle SC  
pHi 6.9



EMT?



Stem-like?

**C**